N/A N=92 Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study
Ventricular Septal Defects
Primary: Primary Effectiveness End Point: Technical Success — 75 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=75 An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)
Ventricular Mural Thrombosis
Primary: Number of Participants With Left Ventricular Thrombus Resolution at 12 Weeks/Number of Participants at 12 Weeks — 50 Participants
N/A N=26 Magnetic Stimulation to Treat VT Storm
Ventricular Tachycardia
Primary: Ventricular Tachycardia - Incidence of Ventricular Tachycardia on Inpatient Telemetry Monitoring — 7; 4 Participants
Phase 3 N=27 Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus
Left Ventricular Thrombosis
Primary: Percent Change in Left Ventricular Thrombus (LVT) Size — -61.45; -65.08 percentage of change
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
N/A N=91 Closure of Muscular Ventricular Septal Defects With The AMPLATZER™ Muscular VSD Occluder
Heart Septal Defects, Ventricular
Primary: Closure of Muscular Ventricular Septal Defects — 91 participants
N/A N=18 Multimodality Assessment of Ventricular Scar Arrhythmogenicity.
Ventricular Tachycardia
Primary: Electrogram Duration at Digital Twin Predicted Sites Compared to Non-predicted Sites — 77.5; 65.7 ms
Phase 2 N=52 Clinical Trial on Treatment of Intraventricular Hemorrhage
Intraventricular Hemorrhage
Primary: 30-day Mortality — 1; 1; 6 Number of participants
Phase 4 N=53 Stereotaxis Study To Obliterate Persistent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Percentage of Participants Free From VT at 1 Year Post-Treatment — 62 percentage of participants free from VT
N/A N=145 Bipolar Ventricular Tachycardia (VT) Study
Ventricular Tachycardia
Primary: Number of Participants Achieving Freedom From Recurrent Ventricular Tachycardia (VT) — 16; 29 Participants
N/A N=76 Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia
Ventricular Tachycardia
Primary: Number of Subjects Without Hospitalization for Ventricular Tachycardia (VT) During 6 Months — 38 Participants
Phase 4 N=249 Catheter Evaluation for Endocardial Ablation in Patients With Ventricular Tachycardia
Ventricular Tachycardia
Primary: The Percentage of Subjects That Expire From All-cause Mortality Within 12-months Post Ablation. — 13.3 percentage of mortality
N/A N=20 Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation
Ventricular Tachycardia
Primary: Number of Participants With Procedural Success — 8; 6 Participants
N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
N/A N=10 Ablation at Virtual-hEart pRedicted Targets for VT
Ventricular Tachycardia · Ischemic Cardiomyopathy
Primary: Number of Participants With Ventricular Tachycardia Inducibility — 6 Participants
N/A N=211 Identifying and Facilitating Ventricular Recovery on Mechanical Support
Heart Failure
Primary: Number of Subjects With Left Ventricular Recovery and LVAD Explant — 8 Participants
N/A N=30 NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation
Mitral Valve Failure
Primary: Number of Participants With "Acceptable" Technical Success of the LAMPOON Procedure — 30; 30; 30; 30 participants
N/A N=82 Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
Phase 3 N=59 ULTrasound Accelerated ThrombolysIs of PulMonAry Embolism
Submassive Pulmonary Embolism
Primary: Reduction of RV/LV Ratio — 0.03; 0.30 Ratio
Phase 3 N=692 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Phase 3 N=231 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)
Aortic Valve Stenosis · Cardiovascular Diseases · Heart Valve Diseases
Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01
N/A N=1,175 Toronto Thromboprophylaxis Patient Safety Initiative
Venous Thromboembolism
Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients
N/A N=103 Assessmet of Patients With PAH Right Ventricular Volume
Pulmonary Arterial Hypertension
Primary: Observed Mean (Std Err) for % Difference Between VMS and MRI. — 4.80; 1.76; 2.03 Percent difference
Phase 2 N=82 Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
N/A N=63 Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Myocardiopathies · Ischemia, Myocardial · Arrythmia
Primary: MMP-2 — 173493.4; 139012.4 pg/ml
N/A N=40 Ablation Targets of Scar-related Ventricular Tachycardia Identified by Dynamic Functional Substrate Mapping
Tachycardia, Ventricular
Primary: Number of Participants With Recurrence of Ventricular Tachycardia — 13; 13 Participants
N/A N=131 The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study
Post-Infarction Ventricular Septal Defect
Primary: Effectiveness Endpoint 1: Technical Success — 76 Participants
N/A N=1 Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
Refractory Ventricular Tachycardia
Primary: ICD (Implantable Cardioverter Defibrillator) Shock Free Survival — 1 Participants
N/A N=120 Training-induced Increased Left Ventricular Trabeculation
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
N/A N=52 Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias
Ventricular Arrythmia
Primary: Number of Participants Who Had Freedom From Ventricular Arrhythmia at 6 Months — 8; 4; 5; 2 Participants